GlaxoSmithKline’s two-drug HIV bet just paid off.

Despite a frantic effort to rush Ebola vaccines through testing during an epidemic, Merck will fall short in its goal to file its candidate this year.

Pfizer faces a legal hurdle to its proposed Herceptin biosimilar now that Roche has sued for patent infringement.

A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."

Pfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions.

Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.

Two of Roche's newest drugs—including the just-approved hemophilia therapy Hemlibra—racked up data that bolster their case for $1 billion-plus sales.

One RBC Capital Markets analyst sees lots of reasons Allergan should break up. A women’s health sale that could bring in billions is just one of them.